Study for the efficacy and safety, the quality of life of patients and the occupational stress of doctors of RAD induction in the treatment of multiple myeloma.

Efficacy and safety of RAD-induced sequential transplantation in the treatment of multiple myeloma, as well as the quality of life of patients and the occupational stress of doctors.

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021558

Enrollment

Unknown

Registered

2019-02-27

Start date

2016-07-01

Completion date

Unknown

Last updated

2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

RAD group:lenalidomide

PAD group:bortezomib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed patients who met the IMWG diagnostic criteria for multiple myeloma in 2014; 2. The age is between 18 and 70 years old, suitable for hematopoietic stem cell transplantation; 3. The behavioral status of ECOG was between 0 - 3, and the expected survival time was more than 6 months; 4. Serum creatinine was normal or creatinine clearance rate = 60 ml/min.

Exclusion criteria

Exclusion criteria: 1. Previous treatment for multiple myeloma; 2. There is a serious underlying disease who not suitable for hematopoietic stem cell transplantation; 3. Creatinine clearance rate < 60 ml/min; 4. A woman who is lactating or pregnant.

Design outcomes

Primary

Measure	Time frame
efficacy;side effect;prognosis and survival;	—

Countries

China

Contacts

Public ContactJuan Li

The First Affiliated Hospital of Sun Yat-sen University

13719209240@163.com+86 13719209240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 16, 2026